EP1018983A4 - Procede pour produire des biomateriaux - Google Patents

Procede pour produire des biomateriaux

Info

Publication number
EP1018983A4
EP1018983A4 EP98906166A EP98906166A EP1018983A4 EP 1018983 A4 EP1018983 A4 EP 1018983A4 EP 98906166 A EP98906166 A EP 98906166A EP 98906166 A EP98906166 A EP 98906166A EP 1018983 A4 EP1018983 A4 EP 1018983A4
Authority
EP
European Patent Office
Prior art keywords
biomaterial
energy absorbing
absorbing material
tissue substrate
outer surfaces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98906166A
Other languages
German (de)
English (en)
Other versions
EP1018983A1 (fr
Inventor
Kenton W Gregory
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SISTERS OF PROVIDENCE IN OREGON
Original Assignee
Providence Health System Oregon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/798,426 external-priority patent/US6110212A/en
Priority claimed from US08/798,425 external-priority patent/US6087552A/en
Application filed by Providence Health System Oregon filed Critical Providence Health System Oregon
Publication of EP1018983A1 publication Critical patent/EP1018983A1/fr
Publication of EP1018983A4 publication Critical patent/EP1018983A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0063—Implantable repair or support meshes, e.g. hernia meshes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/005—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/042—Urinary bladders

Definitions

  • the present invention relates to the biomaterials in tissue repair and replacement.
  • the invention further relates to methods of securing the biomaterials to existing tissue.
  • Collagen is an insoluble fibrous protein that occurs in vertebrates as the chief constituent of connective tissue fibrils and in bones.
  • Fibrin is a white insoluble fibrous protein formed from fibrinogen by the action of thrombin especially in the clotting of blood.
  • Elastin is an extracellular matrix protein that is ubiquitous in mammals.
  • biomaterials include silicone, poly (etherurethane urea) , poly (etherurethane) , poly (esterurethane) , poly (ethylene) , poly (prolene) , poly ( tetrafluoroethylene) , polyvinylidene fluoride, polycarbonate, poly (ethylene terephthlate), poly (methyl methacrylate) , polystyrene, poly (vinylchloride) , poly (2-hydroxyethylmethacrylate) , oly (vinyl- pyrrolidone) , poly (acrylonitrile) , polygycolide, poly (gycolide-L-lactide) , poly (ester-ether) , poly (glycolide-E-caprolactone) copolymer, poly- (glycolide-trimethylene carbonate) , random block copolymer, polyglycolic acid, collagen-based tissues and matrices, tissue engineered materials, bioarti
  • Elastin is an extracellular matrix protein that is ubiquitous in mammals. Elastin is found, for example, in skin, blood vessels, and tissues of the lung where it imparts strength, elasticity and flexibility. In addition, elastin, which is prevalent in the internal elastic lamina (IEL) and external elastic lamina (EEL) of the normal artery, may inhibit the migration of smooth muscle cells into the intima. Elastin in the form of solubilized peptides has been shown to inhibit the migration of smooth muscle cells in response to platelet-derived factors (Ooya a et al, Arter- iosclerosis 7:593 (1987).
  • Elastin repeat hexapeptides attract bovine aortic endothelial cells (Long et al, J. Cell. Physiol. 140:512 (1989) and elastin nonapeptides have been shown to attract fibroblasts (USP 4,976,734).
  • the present invention takes advantage of these physical and biochemical properties of elastin.
  • Prosthetic devices such as vascular stents, have been used with some success to overcome the problems of restenosis or re-narrowing of the vessel wall resulting from ingrowth of muscle cells following injury.
  • prosthetic devices can exacerbate underlying atherosclerosis. Nonetheless, prostheses are often used.
  • Fibrin glue a fibrin polymer polymerized with thrombin, has also been used (primarily in Europe) as a tissue sealant and hemostatic agent.
  • biomaterial suitable for use as a stent for example, a vascular stent, or as conduit replacement, for example, as an artery, vein or a ureter replacement.
  • the biomaterial can also be used as a stent or conduit covering or coating or lining.
  • tissue replacement or repair for example, in interior bladder replacement or repair, intestine, tube replacement or repair such as fallopian tubes, esophagus such as for esophageal varicies, ureter, artery such as for aneurysm, vein, stomach, lung, heart such as congenital cardiac repair, or colon repair or replacement, or skin repair or replacement, or as a cosmetic implantation or breast implant.
  • the subject invention is directed to a method for producing biomaterials which can be used in biomedical applications, or the biomaterial can be fused onto a tissue substrate, or the biomaterial can itself be used.
  • the invention can be also directed to a method for using fusible biomaterial, to a method for producing a biomaterial fused onto a tissue substrate, to a prosthetic device, and to a method of producing a prosthetic device including such biomaterials .
  • the present invention relates to a method of repairing, replacing or supporting a section of a body tissue, preferably a live tissue substrate.
  • the method comprises positioning a biomaterial at the site of the section and bonding the biomaterial to the site or to the tissue surrounding the site.
  • the bonding is effected by contacting the biomaterial and the site, or tissue surrounding the site, at the point at which said bonding is to be effected, with an energy absorbing agent.
  • the agent is then exposed to an amount of energy absorbable by the agent sufficient to bond the biomaterial to the site or to the tissue surrounding the site.
  • a tissue-fusible biomaterial can be produced using the process of the present invention which comprises a layer of a biomaterial and a tissue substrate each having first and second outer surfaces, and an energy absorbing material applied to at least one of the outer surfaces.
  • the energy absorbing material penetrates into the biomaterial .
  • the energy absorbing material is energy absorptive within a predetermined range of light wavelengths depending on material thickness.
  • the energy absorbing material is chosen so that when it is irradiated with light energy in the predetermined wavelength range, the intensity of that light will be sufficient to fuse together one of the first and second outer surfaces of the biomaterial and the tissue substrate.
  • the first and second outer surfaces of the biomaterial are major surfaces.
  • the energy absorbing material is indirectly irradiated by directing the light energy first through the biomaterial or tissue substrate and then to the energy absorbing material.
  • the energy absorbing material comprises a biocompatible chromophore, more preferably an energy absorbing dye.
  • the energy absorbing material is substantially dissipated when the biomaterial and the tissue substrate are fused together.
  • the energy absorbing material comprises a material for staining the first or second surface of the biomaterial .
  • the energy absorbing, material can also be applied to one of the outer surfaces of the biomaterial by doping a separate biomaterial layer with an energy absorbing material and then fusing the doped separate biomaterial layer to the biomaterial.
  • the energy absorbing layer is preferably substantially uniformly applied to a portion of at least one of the outer surfaces, and more preferably in a manner wherein the energy absorbing material substantially covers substantially the entire outer surface of the bio- material .
  • the energy absorbing material can be applied directly to the tissue substrate, it is not the preferred method because of the difficulty in controlling penetration into the intertices of the tissue substrate.
  • Some of the key properties which effect the process of the present invention regarding fusing the biomaterial and tissue substrate include the magnitude of the wave length, energy level, absorption, and light intensity during irradiation with light energy of the energy absorbing material, and the concentration of the energy absorbing material . These properties are arranged so that the temperature during irradiation with light energy for period of time which will cause fusing together of one of the first and second outer surfaces of the biomaterial and the tissue substrate is from about 40 to 140 degrees C, and more preferably from about 50 to 100 degrees C, but if well localized to the biomaterial tissue interface can be as high as 600 degrees C. Furthermore, the average thickness of the energy absorbing material in the preferred process of this invention is from about 0.5 to 300 microns.
  • the subject invention provides a biocompatible biomaterial formed into a three-dimensional structure.
  • This structure can be used, for example, in a stromal support matrix populated with actively growing stromal cells.
  • the stromal support matrix which are preferably fibroblasts, can then be used to provide support, growth factors, and regulatory factors needed to sustain long-term active proliferation of cells in culture.
  • a living stromal tissue can be prepared ' comprising stromal cells and connective tissue proteins naturally secreted by the stromal cells which are attached to and substantially enveloping a framework composed of a biocompatible, non-living material formed into three dimensional structure having interstitial spaces bridged by the stromal cells.
  • the stromal cell systems contemplated herein are described in the following U.S.
  • the biomaterial structures can also have a cellular lining of human cells .
  • the cells can be derived autologously, or otherwise, and formed into a lining on one of the major surfaces of the elastin and elastin-based biomaterials layer.
  • the cells which are employed to form, such a lining are endothelial cells and/or epithelial cells and/or urothelial cells .
  • the present invention also relates to a method of repairing, replacing or supporting a section of a body tissue using biomaterials .
  • the method comprises positioning biomaterials at the site of the section and bonding the biomaterial to the site or to the tissue surrounding the site.
  • the bonding is effected by contacting the biomaterial and the site, or tissue surrounding the site, at the point at which said bonding is to be effected, with an energy absorbing agent .
  • the agent is then exposed to an amount of energy absorbable by the agent sufficient to bond the biomaterial to the site or to the tissue surrounding the site.
  • the absorbing material can comprise biocompatible materials, preferably energy absorbing dye.
  • the energy absorbing material is substantially dissipated when the biomaterial and the tissue substrate are fused together.
  • the energy absorbing material comprises a material for staining the first or second surface of the elastin or elastin-based biomaterial.
  • the energy absorbing material can also be applied to one of the outer surfaces of the biomaterial by doping a separate elastin layer with an energy absorbing material and then fusing the doped separate elastin layer to the biomaterials.
  • the energy absorbing layer is preferably substantially uniformly applied to at least one of the outer surfaces, typically in a manner wherein the energy absorbing material substantially covers the entire outer surface of the biomaterial.
  • Some of the key properties which effect the method of the present invention regarding fusing the biomaterial and tissue substrate include the magnitude of the wavelength, energy level, absorption, and light intensity during irradiation with light energy of the energy absorbing material, and the concentration of the energy absorbing material .
  • the temperature during irradiation with light energy for period of time which will cause fusing together of one of the first and second outer surfaces of the biomaterial and the tissue substrate is from about 40 to 140 degrees C, and more preferably from about 50 to 100 degrees C, but if well localized to the biomaterial tissue interface can be as high as 600 degrees C.
  • the average thickness of the energy absorbing material in the preferred method of this invention is from about 0.5 to 300 microns.
  • FIGURE 1 Application of laser energy to biomaterial and exposed native tissue.
  • FIGURE 2 Placement of biomaterial into artery.
  • FIGURE 3 Use of biomaterial as intestinal patch.
  • FIGURE 4 Scanning electron micrograph of biomaterial (prepared according to Rabaud et al using elastin, fibrinogen and thrombin) fused to porcine aorta using continuous wave diode laser.
  • Biomaterials suitable for use in the present invention can be prepared, for example, from elastin (from bovine nuchal ligament), fibrinogen and thro bin as described by Rabaud et al (USP 5,223,420), as well as from collagen, fibrin, and various other known biomaterials. (See also Aprahamian et al, J. Biomed. Mat. Res. 21:965 (1987); Rabaud et al, Thromb. Res. 43:205 (1986); Martin, Biomaterials 9:519 (1988).
  • Biomaterials suitable for use in the invention can also be prepared from elastin and type III collagen, also as described by Rabaud and co-workers (Lefebvre et al, Biomaterials 13(l):28-33 (1992) . Such preparations are not thrombogenic and thus can be used for vascular stents, etc.
  • a further type of biomaterial suitable for use in the present invention is prepared as described by Urry et al (see, for example, USP 4,132,746 and 4,500,700) (See also USP's 4,187,852, 4,589,882, 4,693,718, 4,783,523, 4,870,055, 5,064,430, 5,336,256).
  • Elastin matrices resulting from digestion of elastin-containing tissues can also be used. Digestion results in the removal of cells, proteins and fats but maintenance of the intact elastin matrix.
  • the biomaterial used will depend on the particular application.
  • Biomaterial of the invention prepared from soluble elastin can be molded so as to render it a suitable size and shape for any specific purpose. Molded biomaterial can be prepared as follows. Elastin (eg soluble elastin MW 12-32,000 daltons) is washed and swollen in buffer. Fibrinogen or cryoglobulins (prepared, for example, according to Pool et al, New Engl . J. Med. 273 (1965 are added to the swollen elastin, followed by thiourea, with or without a protease inhibitor (such as aprotinin) , and collagen.
  • Elastin eg soluble elastin MW 12-32,000 daltons
  • Fibrinogen or cryoglobulins prepared, for example, according to Pool et al, New Engl . J. Med. 273 (1965 are added to the swollen elastin, followed by thiourea, with or without a protease inhibitor (
  • Thrombin is added with stirring and the resulting mixture is immediately poured into an appropriate mold.
  • the mold is then incubated (for example, at 37° C) while polymerization of the fibrin/elastin material is allowed to proceed, advantageously, for from between 15 minutes to 1 hour, 30 minutes being preferred.
  • the reaction can be carried out at temperatures less than 37°C., but the reaction proceeds more rapidly at 77°C. Heating the reaction to over 40°C, however, can result in denaturation of the thrombin. Cooling of the mixture while stirring allows more time for mixing to occur. For polymerization to occur, it is important to have calcium and magnesium in the buffer and to use undenatured thrombin .
  • the resulting biomaterial can be further cross-linked using gamma radiation or an agent such as glutaraldehyde (a solution of glutaraldehyde, formic acid and picric acid being preferred) .
  • glutaraldehyde a solution of glutaraldehyde, formic acid and picric acid being preferred
  • the samples are, advantageously, subjected to gamma-irradiation from a Cobalt-60 source.
  • the amount of irradiation can range, for example, from 10 to 10OMRAD, with 25MRAD being preferred. It has been shown that the amount of gamma-irradiation can affect the strength of the material (Aprahamian, J. Biomed. Mat. Res. 21:965 (1987) .
  • Sheets of biomaterial can be prepared that are of a controlled thicknesses by using appropriate molds .
  • Sheets of the biomaterial can be made in thicknesses ranging, for example, from 200 microns to 5 mm. Sheets are generally made as thin as possible to allow for penetration of laser energy while maintaining sufficient strength.
  • a sheet suitable for use as an intestinal patch can range in thickness from 200 microns to 5 mm, with about 2 mm being preferred.
  • a patch requiring greater strength, such a patch for use in the bladder, is typically thicker.
  • Arterial stents or patches can be thinner (eg 100 ⁇ - 1000 ⁇ m) .
  • Biomaterial prepared from soluble elastic or insoluble elastin fragments can also be molded into tubular segments for example, by injecting the material into tubular molds. Crosslinkage of the elastin solution present between the inner and outer tubes can be effected prior to withdrawal of biomaterial from the mold or after the tubes are removed. Tubular segments of different inner and outer diameters, as well as of different lengths, can be prepared using this approach by varying the diameters of the inner and outer tubes . A mold of this type can be made in virtually any size with the inner and outer tubes varying in diameter. A small tube can be used for a coronary arterial stent.
  • biomaterial suitable for use in the present invention can be prepared from digests of tissue containing an elastin matrix.
  • Tissues suitable for use as a starting material include arteries (e.g. coronary or femoral arteries, for example, from swine), umbilical cords, intestines, ureters, etc.
  • the matrix material is (derived from the species of animal in which the implantation is being performed so that bio- compatibility is increased.
  • Any method of removing (digesting away) cellular material, proteins and fats from the native matrix while leaving the extracellular elastin matrix intact can be used. These methods can involve a combination of acidic, basic, detergent, enzymatic, thermal or erosive means, as well as the use of organic solvents. This may include incubation in solutions of sodium hydroxide, formic acid, trypsin, guanidine, ethanol, diethylether, acetone, t-butanol, and sonication. Typically, the digestion proceeds more quickly at higher temperatures . The optimal temperature and time (of incubation depend on the starting material and digestive agent used, and can be readily determined.
  • tubular segments result from digestion of tubular starting materials
  • those segment can be opened and shaped to yield sheets suitable for use as tissue grafts .
  • such segments can be opened and then reconstructed as tubular segments having a diameter different than the starting tissue.
  • the starting material is selected so as to yield a tubular segment after digestion having the appropriate diameter so that subsequent manipulations (other than adjustment of length) can be avoided.
  • the biomaterial of the invention whether prepared from elastin powder or from tissues digests, is normally secured to existing tissue. Various techniques for effecting that attachment can be used, including art-recognized techniques.
  • the biomaterial be secured using a tissue welding energy source and an agent that absorbs energy emitted by that source.
  • the energy source is an electromagnetic energy source, such as a laser
  • the absorbing agent is a dye having an absorption peak at a wavelength corresponding to that of the laser.
  • the elastin biomaterial and the tissue to be welded have much less absorption of light at this wavelength and the effect therefore is confined to a zone around the dye layer.
  • a preferred energy source is a laser diode having a dominant wavelength at about 808 nm and a preferred dye is indocyanine green (ICG), maximum absorbance 795-805 nm (see WO 91/, 4073). Other laser/dye combinations can also be used.
  • the dye be applied to that portion of the biomaterial that is to be contacted with and secured to the existing tissue.
  • the dye can also be applied to the surface of the structure to which the elastin biomaterial is to be welded or secured.
  • the dye can be applied directly to the biomaterial or the surface of the biomaterial can first be treated or coated (eg primed) with a composition that controls absorption of the dye into the biomaterial so that the dye is kept as a discrete layer or coating.
  • the dye can be bound to the elastin biomaterial so that it is secured to the surface and prevented from leeching into the material .
  • the dye can be applied in the form of a solution or the dye can be dissolved in or suspended in a medium which then can be applied as a thin sheet or film, preferably, of uniform thickness and dye concentration.
  • Tissue welding techniques employing a soldering agent can be used. Such techniques are known (WO 91/04073). Any proteinaceous material that thermally denatures upon heating can be used as the soldering agent (for example, any serum protein such as albumin, fibronectin, Von Willebrand factor, vitronectin, or any mixture of proteins or peptides) . Solders comprising thrombin polymerized fibrinogen are preferred, except where such materials would cause undesirable thrombosis or coagulation such as within vascular lumens. Solders are selected for their ability to impart greater adhesive strength between the biomaterial and the tissue. The solder should be non-toxic and generally biocompatible .
  • the laser energy can be directed to the target site (eg, the dye) directly from the laser by exposure of the tissue (eg, during a surgical procedures) .
  • the laser energy is directed to the bonding site via optical fibers.
  • ICG is used as the dye
  • targeting media wavelengths of around 800nm can be used. Such wavelengths are not well absorbed by many tissues, particularly vascular tissues, therefore, there will be a negligible effect on these tissues and thermal effects will be confined to the dye layer.
  • the biomaterial of the invention similarly has little optical absorbance in this waveband, as compared to the energy absorbing dye.
  • the laser energy can pass through either the biomaterial or the native tissue and be absorbed by the dye layer as shown in Figure 1.
  • the dye-containing surface of the biomaterial is placed in contact with the native tissue at the site and laser energy delivered by directing the laser beam to the desired location.
  • the absorbance of the dye (eg ICG) layer is ideally previously or concurrently determined so that the optimal amount of light for optimal bonding can be delivered.
  • Pressure can be used to ensure adequate approximation of the tissue and biomaterial.
  • the diode laser itself, or a condenser or optical fiber based optical delivery system can be placed against the material to ensure uniform light delivery.
  • the biomaterial is then put in place, dye side down (see Figure 2) .
  • the biomaterial can be deployed as a flat patch or as a tubular segment.
  • a tubular segment can be hollow or filled with a material that supports the lumen during placement and that is melted with low grade heat or dissolved or removed with a variety of means.
  • a small number of surgical sutures eg stay sutures
  • the laser energy is directed through the vessel wall or through the biomaterial to the absorbing dye, the appropriate laser energy having been previously determined based upon the measured absorbance in the biomaterial .
  • the dye can be applied at the time of the surgery to the biomaterial or the vessel wall or both and then laser energy delivered.
  • absorbance can be determined at the time of the surgery to the biomaterial or the vessel wall or both and then laser energy delivered or with a feedback device that assesses the adequacy of the bonding or thermal effect.
  • Figure 4 is a SEM of elastin-based biomaterial fused to porcine aorta.
  • the biomaterial of the invention can be used as a patch material for use in intestinal or colon repairs which frequently do not heal well with current techniques, particularly when the patient has nutritional or other problems or when the patient is in shock, such as in the case of multiple gunshot wounds or other abdominal injuries (see Figure 3) .
  • the use of such a patch can, for example, seal off intestinal contents and thereby reduce the likelihood of peritonitis.
  • a patch can be used on a solid organ, such as the liver, when lacerations have occurred.
  • the biomaterial of the invention can be used to repair or replace portions of the urinary system i.e., from the calyces of the kidney on down to the urethra.
  • the patch can also be used to seal a defect in a cardiac chamber, such as an atrial septal defect, as well as bronchial or rectal fistulas .
  • the biomaterial can also be used as a cerebrovascular patch for an aneurysm.
  • the biomaterial can be sealed in place with targeted laser fusion.
  • a variety of catheter or endoscopic systems can be employed to direct the laser energy to the target site.
  • the elastin-based biomaterials to which the invention relates can be used in a variety of other clinical and surgical settings to effect tissue repair graft.
  • the biomaterial can be pre-mounted upon a deflated balloon catheter.
  • the balloon catheter can be maneuvered into the desired arterial or venous location using standard techniques .
  • the balloon can then be inflated, compressing the stent (biomaterial) against the vessel wall and then laser light delivered through the balloon to seal the stent in place (the dye can be present on the outside of the biomaterial) .
  • the balloon can then be deflated and removed leaving the stent in place.
  • a protective sleeve (eg of plastic) can be used to protect the stent during its passage to the vessel and then withdrawn once the stent is in the desired location.
  • the biomaterial of the invention can also be used as a biocompatible covering for a metal or synthetic scaffold or stent.
  • simple mechanical deployment can be used without the necessity for laser bonding.
  • Laser bonding can be employed, however, depending upon specific demands, eg, where inadequate mechanical bonding occurs, such as in stent deployment for abdominal aortic aneurysms .
  • An alternative catheter-based vascular stent deployment strategy employs a temporary mechanical stent with or without a balloon delivery device.
  • a further catheter-based vascular stent deployment strategy employs a heat deformable metal (such as nitinol or other similar type metal) scaffold or stent or coating that is incorporated into the catheter tubing beneath the stent biomaterial.
  • the stent is maneuvered into the desired location whereupon the deformable metal of the stent is activated such that it apposes the stent against the vessel wall.
  • Laser light is then delivered via an optical fiber based system, also incorporated into the catheter assembly.
  • the biomaterial can also be used to replace portions of diseased or damaged vascular or nonvascular tissue such as esophagus, pericardium, lung plura, etc.
  • the biomaterial can also be used as a skin layer replacement, for example, in burn or wound treatments.
  • the biomaterial serves as a permanent dressing that acts as a scaffolding for epithelial cell regrowth.
  • the biomaterial can include antibiotics, coagulants or other drugs desirable for various treatments that provide high local concentrations with minimal systemic drug levels.
  • the elastin biomaterial can be deployed with a dye on the tissue side and then fused with the appropriate wavelength and laser energy.
  • the biomaterial of the present invention can also be used in organ reconstruction.
  • the biomaterial can be molded or otherwise shaped as a pouch suitable for use in bladder reconstruction.
  • the biomaterial of the invention can also be molded or otherwise shaped so as to be suitable for esophageal replacement.
  • metal or synthetic mesh could also be associated with the implant if extra wall support is needed so as to control passage of food from the pharynx to the stomach. This could be used for stenosis of the esophagus, as a covering for bleeding esophogel varicies to prevent bleeding or to treat bleeding, for repair from acid reflux for erosive esophagitis or, more preferably, for refurbishing damaged esophageal segments during or following surgery or chemotherapy for esophageal carcinoma.
  • the biomaterial of the invention in combination with a supporting material having strong mechanical properties.
  • the biomaterial can be coated on the supporting material (see foregoing stent description) , for example, using the molding techniques described herein.
  • Suitable supporting materials include polymers, such as woven polyethylene terepthalate (Dacron) , teflon, polyolefin copolymer, polyurethane polyvinyl alcohol or other polymer.
  • a polymer that is a hybrid between a natural polymer, such as fibrin and elastin, and a non-natural polymer such as a polyurethane, polyacrylic acid or polyvinyl alcohol can be used (sets Giusti et al , Trends in Polymer Science 1:261 (1993) .
  • a hybrid material has the advantageous mechanical properties of the polymer and the desired biocompatibility of the elastin based material.
  • Examples of other prostheses that can be made from synthetics (or metals coated with the elastin biomaterial or from the biomaterial/ synthetic hybrids include cardiac valve rings and esophageal stents .
  • the prostheses of the invention can be prepared so as to include drug; that can be delivered, via the prostheses, to particular body sites.
  • vascular stents can be produced so as to include drugs that prevent coagulation, such as heparin, or antiplatelet drugs such as hirudin, drugs to prevent smooth muscle ingrowth or drugs to stimulate endothelial damaged esophageal segments during or following surgery or chemotherapy for esophageal carcinoma.
  • the biomaterial of the invention in combination with a supporting material having strong mechanical properties.
  • the biomaterial can be coated on the supporting material (see foregoing stent description) , for example, using the molding techniques described herein.
  • Suitable supporting materials include polymers, such as woven polyethylene terepthalate (Dacron) , teflon, polyolefin copolymer, polyurethane polyvinyl alcohol or other polymer.
  • a polymer that is a hybrid between a natural polymer, such as fibrin and elastin, and a non-natural polymer such as a polyurethane, polyacrylic acid or polyvinyl alcohol can be used (sets Giusti et al, Trends in Polymer Science 1:261 (1993).
  • a hybrid material has the advantageous mechanical properties of the polymer and the desired biocompatibility of the elastin based material.
  • Examples of other prostheses that can be made from synthetics or metals coated with the elastin biomaterial or from the biomaterial/ synthetic hybrids include cardiac valve rings and esophageal stents .
  • the elastin-based prostheses of the invention can be prepared so as to include drug; that can be delivered, via the prostheses, to particular body sites.
  • vascular stents can be produced so as to include drugs that prevent coagulation, such as heparin, drugs to prevent smooth muscle ingrowth or drugs to stimulate endothelial regrowth.
  • vascular stents can be produced so as to include drugs that prevent coagulation, such as heparin, drugs to prevent smooth muscle ingrowth or drugs to stimulate endothelial regrowth.
  • vascular stents can be produced so as to include drugs that prevent coagulation, such as heparin, drugs to prevent smooth muscle ingrowth or drugs to stimulate endothelial regrowth.
  • vascular stents can also be included.
  • Prostheses formed from the elastin based biomaterial can also be coated with viable cells, preferable, cells from the recipient of the prosthetic device. Endothelial cells, preferably autologous (eg harvested during lip
  • the elastin biomaterial can be used as a skin replacement or repair media where cultured skin cells can be placed on the biomaterial prior to implantation. Skin cells can thus be used to coat elastin biomaterial.
  • Biomaterial structures constituting a framework for a three-dimensional, multi-layer cell culture system will provide intact elastic structures not constructed by stromal cells populating synthetic matrices. In vivo elastin production, for example, is thought to only occur during development and ceases during childhood (the only exceptions being hypertension and restenosis) . Elastogenesis is a complex process and formation of mature elastic structures not likely to be achieved in relatively simple in vitro cell culture systems.
  • a method by which to produce a living tissue graft with elastic structure and function most similar to tissue which is high in elastin content is by culturing cells in three dimensional frameworks made of biomaterials . This insures the presence of biologically important elastic structures in the living tissue grafts.
  • a method for both organizing biomaterials fibrils and providing a support for fibroblast growth is by coacervating elastin monomers in solution with fibroblasts.
  • Elastin monomers mixed with stromal cells (fibroblasts) in a physiologic buffer aggregate into fibers (coacervation) upon raising the temperature of the solution. In doing so the fibroblasts become trapped in a loose matrix of elastin fibers .
  • the contraction of the fibroblasts bound to the coacervated elastin monomers could preferentially align the elastin fibrils prior to crosslinking.
  • Phosphate buffer The phosphate buffer used contained 1 mM sodium phosphate, 150 mM sodium chloride, 2 mM calcium chloride, 1 mM magnesium (chloride, pH 7.4.
  • Soluble elastin peptides Bovine ligamentum nuchae elastin powder was obtained from Sigma, St. Louis, Missouri. The following procedure was used to obtain the soluble elastin peptides: 2.7 g elastin powder was suspended in 35 ml of a 1M KOL solution in 80% ethanol. The suspension was stirred at 50° C for 2.5 hr . Next, 10 ml deionized water was added and the solution neutralized with concentrated 12M HCl to pH 7.4.
  • the solution was cooled at 4°C for 12 hrs .
  • the clear solution was decanted from the salt crystals, and the supernatant centrifuged for 15 mins at 2000 rpm.
  • the solution was then dialyzed against three changes of tap water at two hour intervals and one 15 hr interval using a 10,000 MW cutoff dialysis tubing.
  • the dialysis was continued with six changes of deionized water at two hour intervals and one for 15 hrs.
  • the resulting dialyZate was lyophilized and stored at -20°C. The yield was 40%.
  • Cryoglobulin preparation A modification of the method of Pool and Shannon was used to Produce the cryoglobulins (New Engl . J. Med. 273 (1965). Cryoglobulins are principally fibrinogen (40 mg/ml) and fibronectin (10 mg/ml) (concentrations of fibrinogen and fibronectin will vary) . Briefly, blood was collected from swine in a standard 500 ml blood collection bag containing adenine, citrate and dextrose anticoagulant. The blood was transferred to twelve 50 ml plastic centrifuge tubes and centrifuged for 15 mins at 1500 rpm. The plasma was decanted from the erythrocyte layer and frozen at -70°C for 12 hrs.
  • the plasma was then thawed at 4°C.
  • the cryoglobulins were collected by centrifugation of the plasma at 4°C for 15 mins at 1500 rpm. The supernatant was decanted and the cryoglobulins collected by removing the precipitate with a pasteur pipette. Each tube was also rinsed with 3 ml of a sodium citrate solution containing 0.9% NaCI, and 0.66% sodium citrate.
  • the cryoglobulins were pooled, frozen at -70°C, lyophilized and stored at -20°C until use.
  • Thiourea Reagent grade thiourea . was obtained from Sigma, St. Louis, Missouri. A O.S mg/ml solution was used.
  • Type I collagen Acid soluble type I collagen was obtained from Sigma. It was preferred from rat tail tendon by a modification of the method of Bornstein. Two mg of collagen was heated in 0.6 ml phosphate buffer to 60° C for 10 minutes until the collagen dissolved. It was then cooled to 37°C and used.
  • Thrombin from bovine plasma was obtained from Sigma in lyophilized from. When reconstituted with 1 ml water, the solution contained 106 NIH units per ml.
  • Aprotinin Aprotinin from bovin lung was obtained from Sigma. It contained 15-30 trypsin inhibitory units (TIU) per ml. Preparation:
  • the biomaterial was prepared by successively adding and mixing the following: 200 mg soluble kappa-elastin or kappa-elastin powder in 2ml phosphate buffer (PB) (1 mM P041 150 mM NaCI, 2 mM Ca21 1 mM Mg21 PH 7.4) at 37 °C
  • Sheets of biomaterial made as described in Example 1 were equilibrated in phosphate buffer, pH 7.4, and welded to ICG stained porcine aorta using an aluminum gallium arsenide diode array laser.
  • the maximum output was at 808 +/- 1.5nm.
  • the laser was coupled to a l ⁇ m quartz fiber with polyethylene cladding material .
  • the laser energy was collimated with a focusing lens and coupled to the quartz fiber.
  • the spot size at the distal end of the fiber could be varied from 1mm to 4mm by adjusting the distance between the focusing lens and the proximal end of the fiber.
  • the laser operated continuously, CW, and the output measured at the distal end of the fiber was 1.5W.
  • the quartz fiber was positioned directly above the glass slide, biomaterial, aorta. Before welding, the spot size of the laser was measured. Welding appeared to occur under saline at irradiances of 0.85W but not 1.32W. Twenty seconds was sufficient time to weld and 40 seconds caused a brown co:Lor change and charring of the biomaterial .
  • Example 3 Preparation of Elastin-Based Biomaterial from Artery Digest Fresh 4 cm lengths of porcine carotid artery were dissected clean and washed in two changes of 0.9% saline overnight. Vessels were then placed in 0.5M NaOH and sonicated for 120 minutes (a modified method of Crissman, R. 1987) See Crissman, Rogert S. "Comparison of Two Digestive Techniques for Preparation of Vascular Elastic Networks for . SEM Observation", Journal of Electron Microscopy Techniques 6:335-348 (1987) . Digested vessels were then washed in distilled water and autoclaved at 225° F for 30 minutes. Digested vessels appear translucent, pearly white in color and collapsed when removed from water indicating the absence of collagen and other structurally supportive proteins .
  • Example 4 Preparation of Elastin-Based Biomaterial & Fusion to Porcine Aorta Materials: Bovine nuchal elastin powder (Sigma St. Louis MO) was sifted with a 40 ⁇ m screen and swollen with phosphate buffer. Elastin fragments were then reacted with 67 mg of fibrinogen (Sigma): in phosphate buffer, 2m acid soluble Type 1 collagen (Sig ⁇ na) , 2.8 mg thiourea, 2 mM Ca 2+ , lmM Mg+ and 75 units of thrombin and injected into molds and heated to 77° C. One mm thick sheets and tubes of this biomaterial were removed and stored in 33% ethanol for later use.
  • Indocyanine green dye was dissolved in de-ionized water to provide a 1% solution and applied to the lumenal surface of fresh porcine aorta. The dye was in place for 5 minutes then the residual dye was blotted off.
  • the elastin biomaterial was placed on the ICG stained aorta and covered with a glass coverslip. Laser energy was applied with a condenser which collected the output of an array of gallium arsenide diode lasers emitting light at 800nm in 5 msec pulses. Six mm2 Spots were irradiated with 2.89 Joules for 1-10 pulses which provided adequate welds . Samples were then bisected and fixed in formalin for microscopic study.
  • Figure 5 is a light microscopic photograph of such a weld stained with an elastin stain. Excellent welding of the elastin biomaterial to porcine aorta is noted with no detectable thermal or other injury to the biomaterial or aorta.
  • Elastin-fibrin biomaterials was prepared similarly to methods developed by Rabaud (Rabaud) . Patches made of solubilized elastin and cryoprecipates were prepared by successive addition with thorough mixing of 200mg. soluble elastin dissolved in 2 ml buffer, 160 mg . lyophilized cryoprecipitate dissolved in 1 ml buffer, 2 mg type I collagen dissolved in 0.6 ml buffer, and 0.2 ml thiourea solution (o.5 mg/ml H 2 0) . 6 units of thrombin were added to 0.5 ml. aliquots of the mixture, thoroughly mixed in a 1 ml syringe, and injected into 4cm 2 glass molds.
  • the molds were incubated at 37°C for 30 min. and subjected to 25 mrad of ofg-radiation (cobalt source*.
  • the biomaterial was stored at 4°C in 33% etOH. Prior to use the biomaterial was washed several times with saline.
  • Indocyanine green (Sigma) in aqueous concentrated of 1 or 5 mg/ml was applied to aorta via a pasteur pipette, left undisturbed for 5 min. and then blotted away. The tissue was then equilibrated in a 0.9% saline solution for 15 minutes to remove any unbound dye. The biomaterial was then applied to the lumenal surface of the aorta. the laser beam was directed at the biomaterial surface via a 1 ⁇ m fused silica fiber (Polymicro Technologies Phoenix, Az . ) through a glass coverslip as shown in figure 1. the spot size of the laser beam varied between 1-4 mm. The laser output measured from the fiber tip was 1.5 Watts and exposed durations varied from 5 to 4 seconds .
  • the insoluble elastin-fibrinogen patch was fused to porcine aorta using an Aluminum Gallium Arsenide diode array laser emitting 790-810 nm pulsed optical radiation (Star Medical Technologies) .
  • Thawed porcine aorta was prepared and stained with 5mg/ml aqueous ICG solution as previously described for fresh aorta.
  • laser radiation was directed at the biomaterial via a copper coated condenser placed against a glass coverslip.
  • the laser output was set at 2J and 5 msec pulse durations .
  • Example 6 Preparation of Elastin-Based Biomaterials and Fusing of Same Bovine ligamentum nuchae elastin, fibrinogen from porcine plasma, and acid soluble type I collagen from rat tale tendon were obtained from Sigma Chemical Corp. (St . Louis, Mo) .
  • indo cyanine green 1 mg. indo cyanine green is dissolved in 1 ml of 24% human serum albumin. 67 mg of fibrinogen was dissolved in 1 ml phosphate buffer (@37°C) . Just prior to mixing 16.6 units of thrombin are added to the indocyanine green solution. The mixtures were cooled to 4°C. The two mixtures are rapidly mixed and injected, or poured, into a 3 X 7 cm mold and incubated for 30 min. at 37°C. Lyophilized elastin from Sigma was passed through a U.S. No. 400 mesh sieve (Tyler) prior to use. Only the 40 ⁇ m or smaller particles were used.
  • 210 mg of the filtered elastin was swollen and washed overnight in an excess of phosphate buffer. The mixture was centrifuged (1000 rpm, 10 min.) and the excess buffer discarded. The swollen elastin was suspended in 1.5 ml of phosphate buffer. Successively added to this suspension were 67 mg lyophilized fibrinogen dissolved in 0.75 ml buffer, 2 mg type I collagen dissolved in 0.45 ml buffer, and 0.15 ml thiourea solution (0.5mg/ml H 2 0) .
  • Example 7 Welding of elastin fibrin biomaterial to porcine intestine
  • Fresh porcine intestine was obtained from Carlton Packing Co. (Carlton, OR). The intestine was rinsed with tap water and stored at -20° C in Ziploc freezer bags . Prior to use the intestine is thawed in ambient air and kept on saline soaked gauze to prevent drying out .
  • the elastin fibrin biomaterial prepared as described in Example 4 was fused to porcine intestine using a Aluminum Gallium Arsenide diode array laser (Star Medical Technologies) as follows: Indocyanine green in aqueous concentrations of 5 mg/ml was applied to the serosa of thawed porcine intestine with a pasteur pipette, left undisturbed for 5 minutes and then blotted away with a Kimwipe EXL wipe. Elastin-fibrin biomaterial was cut into 1 X 1 cm patches an excess moisture was blotted away with a Kimwipe EXL wipe.
  • Example 8 Preparation and welding of coronary vessel digests.
  • Fresh left anterior descending, right main, and circumflex coronary arteries were excised from a porcine heart. Excess fat and thrombus were removed from the excised vessels. The vessels were cut in half and the distal halves were washed in saline and sonicated in 0.5M NaOH for 45 min at 65°C. The distal halves were then removed from the alkali, immersed in 500 ml distilled water for 30 min, and finally immersed in boiling distilled water for another 30 min. The NaOH-sonicated vessels are hereafter referred to as heterografts . The proximal half of the vessels were saved and stored on saline soaked gauze until use.
  • the heterograft covered balloon was inflated to 4 psi and immersed in the ICG-HSA for 5 minutes to stain the heterograft. After removing the heterograft and balloon from the staining solution, the balloon is deflated and inserted into the untreated proximal half of a right main or LAD coronary artery. Following insertion, the balloon is inflated to 8 psi. The inflated balloon/heterograft is placed on a benchtop and a coverslip is placed over the region to be welded. A 4 X 4 mm copper coated condenser is placed against the coverslip. The laser output was set for 2.3 joules of energy and 5 msec pulse durations.
  • the balloon is rotated approximately 30 degrees and another region is illuminated with 5 pulses . This procedure is repeated until the entire circumference of the balloon has been illuminated.
  • the balloon is then deflated, leaving behind the heterograft, now fused to the luminal surface of the artery.

Abstract

L'objectif général de l'invention est de proposer une méthode permettant de réparer ou de remplacer un tissu au moyen d'un biomatériau. Son objectif spécifique est de proposer un biomatériau pouvant être utilisé comme endoprothèse, endoprothèse vasculaire par exemple, ou comme substitut de conduit, artère, veine ou uretère par exemple. Le biomatériau peut également être utilisé comme couche de protection ou comme revêtement pour une endoprothèse ou un conduit. L'invention concerne une méthode permettant de réparer, de remplacer ou de supporter une partie d'un tissu corporel. Selon la méthode, on positionne un biomatériau au niveau du site de ladite partie et on le fixe sur ledit site ou sur le tissu entourant ce dernier. On fixe le biomatériau en le mettant en contact avec le site, ou avec le tissu entourant ce dernier, au niveau du point où il est destiné à être fixé, au moyen d'un agent absorbant l'énergie. Puis on expose ledit agent à une quantité d'énergie pouvant être absorbée par l'agent, qui est suffisante pour fixer le biomatériau sur le site ou sur le tissu entourant ce dernier.
EP98906166A 1997-02-07 1998-02-06 Procede pour produire des biomateriaux Withdrawn EP1018983A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US798426 1997-02-07
US08/798,426 US6110212A (en) 1994-11-15 1997-02-07 Elastin and elastin-based materials
US08/798,425 US6087552A (en) 1994-11-15 1997-02-07 Method of producing fused biomaterials and tissue
US798425 1997-02-07
PCT/US1998/002243 WO1998036707A1 (fr) 1997-02-07 1998-02-06 Procede pour produire des biomateriaux

Publications (2)

Publication Number Publication Date
EP1018983A1 EP1018983A1 (fr) 2000-07-19
EP1018983A4 true EP1018983A4 (fr) 2006-09-27

Family

ID=27121987

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98906166A Withdrawn EP1018983A4 (fr) 1997-02-07 1998-02-06 Procede pour produire des biomateriaux

Country Status (4)

Country Link
EP (1) EP1018983A4 (fr)
AU (1) AU748911B2 (fr)
CA (1) CA2279907A1 (fr)
WO (1) WO1998036707A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903244B1 (en) * 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
US6866686B2 (en) 2000-01-28 2005-03-15 Cryolife, Inc. Tissue graft
US6764710B2 (en) 2001-07-18 2004-07-20 Scimed Life Systems, Inc. Light emitting markers for use with substrates
ITMI20051854A1 (it) 2005-10-03 2007-04-04 Sambusseti Antonio Patch per la sostituzione di una porzione di parete vescicale a seguito di vescitectomia parziale
DE102006020494A1 (de) * 2006-04-21 2007-10-25 Novalung Gmbh Künstliches Lungensystem und dessen Verwendung
WO2009137793A1 (fr) * 2008-05-09 2009-11-12 The General Hospital Corporation Constructions artificielles de tissus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
WO1996022054A1 (fr) * 1995-01-20 1996-07-25 The Microsearch Foundation Of Australia Procede de reparation de tissus
US5552452A (en) * 1993-03-15 1996-09-03 Arch Development Corp. Organic tissue glue for closure of wounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5209776A (en) * 1990-07-27 1993-05-11 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
AU1444292A (en) * 1991-02-13 1992-09-15 Interface Biomedical Laboratories Corp. Filler material for use in tissue welding
US5669934A (en) * 1991-02-13 1997-09-23 Fusion Medical Technologies, Inc. Methods for joining tissue by applying radiofrequency energy to performed collagen films and sheets
US5690675A (en) * 1991-02-13 1997-11-25 Fusion Medical Technologies, Inc. Methods for sealing of staples and other fasteners in tissue
US5749895A (en) * 1991-02-13 1998-05-12 Fusion Medical Technologies, Inc. Method for bonding or fusion of biological tissue and material
US5716394A (en) * 1994-04-29 1998-02-10 W. L. Gore & Associates, Inc. Blood contact surfaces using extracellular matrix synthesized in vitro
US5643712A (en) * 1994-05-20 1997-07-01 Brasile; Lauren Method for treating and rendering grafts nonthrombogenic and substantially nonimmunogenic using an extracellular matrix coating
AU2517395A (en) * 1994-05-20 1995-12-18 Vec Tec, Inc. Methods rendering grafts nonthrombogenic and substantially nonimmunogenic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
US5552452A (en) * 1993-03-15 1996-09-03 Arch Development Corp. Organic tissue glue for closure of wounds
WO1996022054A1 (fr) * 1995-01-20 1996-07-25 The Microsearch Foundation Of Australia Procede de reparation de tissus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9836707A1 *

Also Published As

Publication number Publication date
WO1998036707A1 (fr) 1998-08-27
AU748911B2 (en) 2002-06-13
CA2279907A1 (fr) 1998-08-27
AU6146698A (en) 1998-09-09
EP1018983A1 (fr) 2000-07-19

Similar Documents

Publication Publication Date Title
US6110212A (en) Elastin and elastin-based materials
US6087552A (en) Method of producing fused biomaterials and tissue
CA2205038C (fr) Biomateriaux constitues d'elastine ou a base d'elastine et procede associe
EP1049482B1 (fr) Procede de production d'elastine, de materiaux a base d'elastine et de materiaux a base de tropoelastine
US7001328B1 (en) Method for using tropoelastin and for producing tropoelastin biomaterials
EP1113765B1 (fr) Stent implantable et production de ce stent
AU737125B2 (en) Method for using tropoelastin and for producing tropoelastin biomaterials
AU748911B2 (en) Method of producing biomaterials
AU767057B2 (en) Method of producing biomaterials
AU746813B2 (en) Prosthetic device and process of production
KR100271014B1 (ko) 엘라스틴 또는 엘라스틴-기초 생체 적합 물질을 이용한 인공 보철물 장치 및 그의 제조 방법
CA2471757A1 (fr) Biomateriaux constitues d'elastine ou a base d'elastine et procede associe
MXPA00006485A (en) Method of producing elastin, elastin-based biomaterials and tropoelastin materials
MXPA97003589A (en) Elastina, biomaterials based on elastin and process for your producc

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990907

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GREGORY, KENTON W.

Owner name: SISTERS OF PROVIDENCE IN OREGON

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GREGORY, KENTON W.

Owner name: PROVIDENCE HEALTH SYSTEM-OREGON

A4 Supplementary search report drawn up and despatched

Effective date: 20060830

17Q First examination report despatched

Effective date: 20070123

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070803